Hospital

New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.

Both of Moderna's bivalent boosters showed neutralizing activity against BQ.1.1, an increasingly dominant emerging variant, confirming that updated vaccines have the potential to offer protection as the virus continues to evolve.

Annie Lambert, PharmD, BCSCP, discusses how to approach the implementation of the revised USP chapter guidelines before the enforcement date in fall 2023.

Teplizumab-mzwv is administered through injection and can delay the onset of type 1 diabetes in adults and pediatric patients.

Brian Serumaga, PhD, of US Pharmacopeia (USP) discusses the revisions to compounding chapters <795> and <797> and the resources available to help pharmacists update their practices.

Bepirovirsen produced sustained clearance of hepatitis B virus and hepatitis B surface antigens.

Dapagliflozin is the first SGLT2 inhibitor approved by the FDA for treatment of patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

Patients administered 75 mg or higher of olpasiran every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36.

The Elecsys NT-proBNP test is an objective biomarker that aids in the diagnosis of individuals believed to have congestive heart failure.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Ponatinib (Iclusig; Takeda) combined with reduced-intensity chemotherapy achieved higher minimal residual disease-negative complete remission rates in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia compared to imatinib.

Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.

Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.

Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.

Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products.

Analysis of central Missouri discovers differences in co-infection occurrence between Delta and Omicron variants.

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

cobas MPXV targets 2 different regions of the monkeypox virus genome that are less prone to mutations than other parts of the genome.

In a 2019 survey, middle-aged participants were considerably more apprehensive about getting vaccinated than younger groups, which was not the case in the 2022 survey.

Technology gains traction in health-system pharmacies for drug inventory and to automate applications.

Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Approximately 80% of all HIV infections among teens are from the gay and bisexual population.

Study suggests states maintaining higher health care expenditures are more attentive to price transparency initiatives and tend to adopt all-payer claims databases.

NVX-CoV2373 is a protein-based vaccine developed from the genetic sequence of the first strain of SARS-CoV-2.

Dapagliflozin and standard of care found to slow the decline in kidney function and lower the incidence of kidney failure.

New COVID-19 variants are always cause for concern but are not a cause for panic.

PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.

Zilucoplan is a subcutaneous, self-administered peptide inhibitor of complement component 5.

GDA-501, a novel, genetically modified, nicotinamide natural killer pre-clinical cell therapy.

Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.